Science & Technology
Peptide-HLA-DQ8 biologics for antigen-specific therapy in Type 1 Diabetes
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R43AI183983-01A1
Award Ceiling
$303K
Award Floor
$303K
Close Date
Jan 31, 2026
Total Funding
$303K
Expected Awards
1
Posted Date
Aug 11, 2025
Cost Sharing Required
No
Grants.gov ID
sbir-1R43AI183983-01A1
Description
SBIR Phase Phase I award: "Peptide-HLA-DQ8 biologics for antigen-specific therapy in Type 1 Diabetes" awarded to Antiger Therapeutics Inc. in SAINT LOUIS, Missouri. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $303,274. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses, Socially/economically disadvantaged, Women-owned businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.